Developer docs
API playgroundTry for free, no card

Search company profiles

Bea Fertility

Full company profile

uuid000246c

Namestring
Bea Fertility
Legal namestring
StepOne Fertility, Inc.
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Bea Fertility (legal entity StepOne Fertility, Inc., d/b/a Béa Fertility) is a fertility technology company that sells an at-home clinical fertility treatment package combining a proprietary FDA-cleared Class II medical device with nurse-led coaching. The core technology is the Béa Applicator — a cervical-cap intracervical insemination (ICI) device developed over four years and 1,000+ design tests that delivers 3.23x more sperm to the cervix than natural intercourse and holds semen against the cervix for up to five hours. Treatment is sold as two tiers: Essential Care at $399 for 3 cycles and Complete Care at $599 for 3 cycles, both HSA/FSA eligible, each kit containing two applicators and sample containers per cycle, and both including a dedicated fertility coach plus access to the Béa Treatment Hub patient portal. The company also operates a B2B2C OB/GYN referral channel with QR-code handoff and a UK NHS pilot program following its 2023 seed raise.

The company is headquartered in London with a US subsidiary in New York (Delaware-incorporated StepOne Fertility, Inc.) and serves customers in all 50 US states plus the UK. GTM is hybrid: direct-to-consumer e-commerce on beafertility.com as the primary channel, a provider-referral network with monthly encrypted progress reports to referring OB/GYNs as the secondary channel, and content marketing across blog, Instagram, Facebook, TikTok, and earned PR as the top-of-funnel motion. Pricing is package-based ($399–$599 for 3-cycle bundles) with Shop Pay Installments and HSA/FSA support. As of 2024 the company had served 1,250+ patients and shipped 3,500+ cycles, with an internal observational 39.28% pregnancy rate over three cycles (versus an often-cited 31% IUI benchmark). Investors include Octopus Ventures (seed lead), Calm/Storm VC, Forward Partners, JamJar Investments, QVentures, 7percent Ventures, and Springboard Enterprises; total disclosed equity funding is ~£2.5M (~$3.7M) in the 2023 seed plus undisclosed extension rounds.

The competitive positioning sits between natural conception (DIY insemination kits like Mosie/PherDal/Frida at ~$135/cycle and a modeled ~17.7% pregnancy rate) and clinic-based IUI (~$1,400/cycle, ~31% over three cycles), with at-home delivery, no medications, and dedicated coaching as differentiators. The product is positioned as hormone-free, OB/GYN-recommended, and supported by clinical-grade materials, with the FDA 510(k) clearance serving as the core regulatory moat. Leadership is co-founder-led (Tess Cosad, CEO; David O'Rourke, CSO/CIO) with a small executive team including a CMO and CMO medical.

Short descriptiontext

Bea Fertility (StepOne Fertility, Inc.) sells an FDA-cleared at-home intracervical insemination device and fertility coaching on a 3-cycle subscription ($399–$599) to individuals and couples trying to conceive, including heterosexual couples, LGBTQ+ families, single parents, and doctor-referred patients in the US and UK.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
at-home fertility treatment, intracervical insemination device, fertility coaching services, FDA-cleared medical device, fertility treatment kits
Industry3 codes
PRIMARYHLALAHAA
Fertility & Reproductive Endocrinology Telehealth (IVF/IUI, infertility evaluation)
Healthcare & Life Sciences/Telehealth Platforms/Women’s & Family Health Telehealth Platforms (fertility, pregnancy, pediatrics)
SECONDARYHLAFAJAD
Fertility, Reproductive Endocrinology & IVF Centers
Healthcare & Life Sciences/Healthcare Providers & Systems/Women’s & Children’s Health Providers
SECONDARYCRABAIAK
Fertility & Ovulation Products (OTC)
NAICS code2 codes
  • Family Planning Centers621410
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
At-Home Fertility Treatment
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Fertility Treatment Kit Sales
TypeHardware Sales
Description

Direct sales of at-home fertility treatment kits to consumers. Two tiers offered: Essential Care ($399 for 3 cycles) and Complete Care ($599 for 3 cycles). Each kit includes applicators, sample collection containers, and access to the Béa Treatment Hub. HSA/FSA eligible.

beafertility.com
2Fertility Coaching Services
TypeProfessional Services
Description

Included as part of treatment packages. Essential Care includes one 15-minute setup consultation with fertility coach. Complete Care includes three 30-minute video consultations (one per cycle) plus ongoing coach access via SMS/email Monday-Friday. Coaching provided by registered nurses and fertility specialists.

beafertility.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Pricing details2 tiers
1Essential Care - $399 for 3-cycles (~$133/cycle)
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Includes 3 Béa treatment cycles, 6 Béa Applicators for 2 insemination attempts per cycle, 1x setup-focused video consultation with fertility coach, and on-demand SMS/email support (5 days/week).

beafertility.com
2Complete Care - $599 for 3-cycles (~$199.66/cycle)
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Recommended tier. Includes everything in Essential Care plus 3x video consultations (one per cycle), coordinated care with dedicated fertility coach, and care management hub for tracking and uploads.

beafertility.com
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Bea Fertility sells at-home fertility treatment kits that include an FDA-cleared Class II intracervical insemination applicator with cervical cap technology, bundled with a digital Treatment Hub and one-on-one fertility coaching delivered by trained clinicians. The kits are marketed to individuals and couples (heterosexual, LGBTQ+, and single parents by choice) seeking an at-home alternative between timed intercourse and clinical IUI.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 39.28% pregnancy rate over 3 cycles (vs. 31% for IUI over 3 cycles)
+5 more records
Product overview1 text field

Béa Fertility offers an at-home clinical fertility treatment platform combining its proprietary FDA-cleared Béa Applicator (an intracervical insemination device) with fertility coaching services. The core product portfolio includes two treatment tiers: Essential Care ($399/3-cycles) with light-touch support, and Complete Care ($599/3-cycles) with comprehensive coaching. The centerpiece is the Béa Applicator, a cervical-cap device that delivers 3.23x more sperm to the cervix than natural intercourse. Treatment is supported through the Béa Treatment Hub patient portal and dedicated Fertility Coach services. All products are HSA/FSA eligible.

Product and service2 records
1Béa Treatment - Essential Care
CategoryAt-home fertility treatment kit
Description

Three-cycle at-home fertility treatment kit sold for $399, including Béa Applicators, consumable Insemination Kits, Pregnancy Tests, access to the Béa Treatment Hub digital portal, and entry into the Béa fertility coaching community. Designed for individuals and couples seeking a clinician-supported at-home intracervical insemination option before escalating to clinical IUI.

2Béa Treatment - Complete Care
CategoryAt-home fertility treatment kit
Description

Six-cycle at-home fertility treatment kit sold for $599, including Béa Applicators, consumable Insemination Kits, Pregnancy Tests, full Treatment Hub access, and 1:1 video fertility coaching sessions with a trained fertility clinician. Designed for higher-commitment buyers who want longer protocols and dedicated 1:1 clinician coaching.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-07-31
Description

Béa Fertility launched a pilot program with the NHS following their £2.5 million funding round. The NHS pilot enables NHS patients to access Béa's at-home fertility treatment kits, expanding access to fertility care through the public healthcare system. This represents a significant validation of the technology and a strategic channel for UK market penetration.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Natalist sells DTC fertility and conception products (tests, supplements, lubricants). It overlaps with Béa on the TTC consumer journey but does not offer a medical insemination device.

TypeDirect peer
Description

Mosie Baby sells the most well-known DTC at-home intracervical insemination syringe kit in the US. Béa is positioned as a more clinically-supported, FDA-cleared alternative to Mosie's syringe-based approach at a comparable per-cycle price.

TypeDirect peer
Description

PherDal sells a sterile, FDA-registered at-home insemination kit targeting TTC couples and LGBTQ+ families. Béa competes on a similar use case but with FDA Class II clearance and bundled coaching.

TypeDirect peer
Description

Frida has expanded from baby care into fertility, including an at-home insemination syringe kit. Same consumer segment as Béa but without FDA-cleared device status or integrated coaching.

TypeEmerging player
Description

Modern Fertility (acquired by Ro) sells at-home hormone testing and fertility insights. It targets the same pre-clinical fertility consumer but is positioned upstream of treatment, whereas Béa is a treatment itself.

TypeBroad incumbent
Description

Maven is a leading women's and family health virtual care platform serving employers and payers. It overlaps with Béa in fertility coaching and virtual care but does not ship a hardware insemination device.

TypeBroad incumbent
Description

Carrot is a global fertility benefits platform for employers. It is a potential channel partner and adjacent competitor for Béa's fertility services, particularly for employer-sponsored adoption.

TypeBroad incumbent
Description

Kindbody operates fertility clinics and employer-benefit programs across the US. As a clinic-based provider, it competes with Béa on the 'where to get treated' decision rather than on at-home ICI.

TypeBroad incumbent
Description

Progyny provides employer-sponsored fertility benefits covering IUI/IVF at partner clinics. Béa could be positioned as a lower-cost pre-IUI step within a Progyny-style benefit design.

TypeEmerging player
Description

OvuSense offers fertility tracking sensors and apps for ovulation prediction. It overlaps with Béa on cycle timing and TTC consumer engagement but does not deliver an insemination treatment.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bea Fertility

At-Home Fertility Treatmentbeafertility.com

Bea Fertility (StepOne Fertility, Inc.) sells an FDA-cleared at-home intracervical insemination device and fertility coaching on a 3-cycle subscription ($399–$599) to individuals and couples trying to conceive, including heterosexual couples, LGBTQ+ families, single parents, and doctor-referred patients in the US and UK.

What Bea Fertility does

Bea Fertility (legal entity StepOne Fertility, Inc., d/b/a Béa Fertility) is a fertility technology company that sells an at-home clinical fertility treatment package combining a proprietary FDA-cleared Class II medical device with nurse-led coaching. The core technology is the Béa Applicator — a cervical-cap intracervical insemination (ICI) device developed over four years and 1,000+ design tests that delivers 3.23x more sperm to the cervix than natural intercourse and holds semen against the cervix for up to five hours. Treatment is sold as two tiers: Essential Care at $399 for 3 cycles and Complete Care at $599 for 3 cycles, both HSA/FSA eligible, each kit containing two applicators and sample containers per cycle, and both including a dedicated fertility coach plus access to the Béa Treatment Hub patient portal. The company also operates a B2B2C OB/GYN referral channel with QR-code handoff and a UK NHS pilot program following its 2023 seed raise.

The company is headquartered in London with a US subsidiary in New York (Delaware-incorporated StepOne Fertility, Inc.) and serves customers in all 50 US states plus the UK. GTM is hybrid: direct-to-consumer e-commerce on beafertility.com as the primary channel, a provider-referral network with monthly encrypted progress reports to referring OB/GYNs as the secondary channel, and content marketing across blog, Instagram, Facebook, TikTok, and earned PR as the top-of-funnel motion. Pricing is package-based ($399–$599 for 3-cycle bundles) with Shop Pay Installments and HSA/FSA support. As of 2024 the company had served 1,250+ patients and shipped 3,500+ cycles, with an internal observational 39.28% pregnancy rate over three cycles (versus an often-cited 31% IUI benchmark). Investors include Octopus Ventures (seed lead), Calm/Storm VC, Forward Partners, JamJar Investments, QVentures, 7percent Ventures, and Springboard Enterprises; total disclosed equity funding is ~£2.5M (~$3.7M) in the 2023 seed plus undisclosed extension rounds.

The competitive positioning sits between natural conception (DIY insemination kits like Mosie/PherDal/Frida at ~$135/cycle and a modeled ~17.7% pregnancy rate) and clinic-based IUI (~$1,400/cycle, ~31% over three cycles), with at-home delivery, no medications, and dedicated coaching as differentiators. The product is positioned as hormone-free, OB/GYN-recommended, and supported by clinical-grade materials, with the FDA 510(k) clearance serving as the core regulatory moat. Leadership is co-founder-led (Tess Cosad, CEO; David O'Rourke, CSO/CIO) with a small executive team including a CMO and CMO medical.

Bea Fertility firmographics

Firmographics
Name
Bea Fertility
Legal name
StepOne Fertility, Inc.
Website
https://beafertility.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Bea Fertility (StepOne Fertility, Inc.) sells an FDA-cleared at-home intracervical insemination device and fertility coaching on a 3-cycle subscription ($399–$599) to individuals and couples trying to conceive, including heterosexual couples, LGBTQ+ families, single parents, and doctor-referred patients in the US and UK.
Ownership category
akta.pro rank

Bea Fertility industry classification

Industry
Product category
At-Home Fertility Treatment
NAICS
Family Planning Centers (621410), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLALAHAA
Fertility & Reproductive Endocrinology Telehealth (IVF/IUI, infertility evaluation)
Healthcare & Life Sciences/Telehealth Platforms/Women’s & Family Health Telehealth Platforms (fertility, pregnancy, pediatrics)
SECONDARYHLAFAJAD
Fertility, Reproductive Endocrinology & IVF Centers
Healthcare & Life Sciences/Healthcare Providers & Systems/Women’s & Children’s Health Providers
SECONDARYCRABAIAK
Fertility & Ovulation Products (OTC)

Keywords

  • At-home fertility treatment
  • Intracervical insemination device
  • Fertility coaching services
  • FDA-cleared medical device
  • Fertility treatment kits

Where Bea Fertility is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Bea Fertility business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Fertility Treatment Kit Sales: Direct sales of at-home fertility treatment kits to consumers. Two tiers offered: Essential Care ($399 for 3 cycles) and Complete Care ($599 for 3 cycles). Each kit includes applicators, sample collection containers, and access to the Béa Treatment Hub. HSA/FSA eligible.
  2. Fertility Coaching Services: Included as part of treatment packages. Essential Care includes one 15-minute setup consultation with fertility coach. Complete Care includes three 30-minute video consultations (one per cycle) plus ongoing coach access via SMS/email Monday-Friday. Coaching provided by registered nurses and fertility specialists.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractEssential Care - $399 for 3-cycles (~$133/cycle)
SubscriptionMulti-year contractComplete Care - $599 for 3-cycles (~$199.66/cycle)

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Bea Fertility product offering

Product offering

Core offering

Bea Fertility sells at-home fertility treatment kits that include an FDA-cleared Class II intracervical insemination applicator with cervical cap technology, bundled with a digital Treatment Hub and one-on-one fertility coaching delivered by trained clinicians. The kits are marketed to individuals and couples (heterosexual, LGBTQ+, and single parents by choice) seeking an at-home alternative between timed intercourse and clinical IUI.

Product overview

Béa Fertility offers an at-home clinical fertility treatment platform combining its proprietary FDA-cleared Béa Applicator (an intracervical insemination device) with fertility coaching services. The core product portfolio includes two treatment tiers: Essential Care ($399/3-cycles) with light-touch support, and Complete Care ($599/3-cycles) with comprehensive coaching. The centerpiece is the Béa Applicator, a cervical-cap device that delivers 3.23x more sperm to the cervix than natural intercourse. Treatment is supported through the Béa Treatment Hub patient portal and dedicated Fertility Coach services. All products are HSA/FSA eligible.

Differentiator

Problem solved

Functional benefit

Products and services

  • Béa Treatment - Essential Care Three-cycle at-home fertility treatment kit sold for $399, including Béa Applicators, consumable Insemination Kits, Pregnancy Tests, access to the Béa Treatment Hub digital portal, and entry into the Béa fertility coaching community. Designed for individuals and couples seeking a clinician-supported at-home intracervical insemination option before escalating to clinical IUI.
  • Béa Treatment - Complete Care Six-cycle at-home fertility treatment kit sold for $599, including Béa Applicators, consumable Insemination Kits, Pregnancy Tests, full Treatment Hub access, and 1:1 video fertility coaching sessions with a trained fertility clinician. Designed for higher-commitment buyers who want longer protocols and dedicated 1:1 clinician coaching.

Quantifiable outcome

  • 39.28% pregnancy rate over 3 cycles (vs. 31% for IUI over 3 cycles)
  • +5 more outcomes

Companies that use Bea Fertility

Customer profile

Named customers3 records

Segments5 records

Ideal customer profiles5 records

Bea Fertility technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Bea Fertility partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • NHS (UK National Health Service)coreStrategic or Co-development Partner · 31 July 2023Béa Fertility launched a pilot program with the NHS following their £2.5 million funding round. The NHS pilot enables NHS patients to access Béa's at-home fertility treatment kits, expanding access to fertility care through the public healthcare system. This represents a significant validation of the technology and a strategic channel for UK market penetration.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Bea Fertility competitors and assessment

Company assessment

Emerging players

  • Natalist: Natalist sells DTC fertility and conception products (tests, supplements, lubricants). It overlaps with Béa on the TTC consumer journey but does not offer a medical insemination device.
  • Modern Fertility: Modern Fertility (acquired by Ro) sells at-home hormone testing and fertility insights. It targets the same pre-clinical fertility consumer but is positioned upstream of treatment, whereas Béa is a treatment itself.
  • OvuSense: OvuSense offers fertility tracking sensors and apps for ovulation prediction. It overlaps with Béa on cycle timing and TTC consumer engagement but does not deliver an insemination treatment.

Direct peers

  • Mosie Baby: Mosie Baby sells the most well-known DTC at-home intracervical insemination syringe kit in the US. Béa is positioned as a more clinically-supported, FDA-cleared alternative to Mosie's syringe-based approach at a comparable per-cycle price.
  • PherDal: PherDal sells a sterile, FDA-registered at-home insemination kit targeting TTC couples and LGBTQ+ families. Béa competes on a similar use case but with FDA Class II clearance and bundled coaching.
  • Frida (Frida Fertility): Frida has expanded from baby care into fertility, including an at-home insemination syringe kit. Same consumer segment as Béa but without FDA-cleared device status or integrated coaching.

Broad incumbents

  • Maven Clinic: Maven is a leading women's and family health virtual care platform serving employers and payers. It overlaps with Béa in fertility coaching and virtual care but does not ship a hardware insemination device.
  • Carrot Fertility: Carrot is a global fertility benefits platform for employers. It is a potential channel partner and adjacent competitor for Béa's fertility services, particularly for employer-sponsored adoption.
  • Kindbody: Kindbody operates fertility clinics and employer-benefit programs across the US. As a clinic-based provider, it competes with Béa on the 'where to get treated' decision rather than on at-home ICI.
  • Progyny: Progyny provides employer-sponsored fertility benefits covering IUI/IVF at partner clinics. Béa could be positioned as a lower-cost pre-IUI step within a Progyny-style benefit design.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Bea Fertility social profiles

Digital presence

Bea Fertility compliance and trust

Trust signal

Compliance2 records

Bea Fertility financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bea Fertility leadership team

Management profile

Number of profiles

Profiles4 records

Bea Fertility funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bea Fertility M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bea Fertility

What does Bea Fertility do?

Bea Fertility sells at-home fertility treatment kits that include an FDA-cleared Class II intracervical insemination applicator with cervical cap technology, bundled with a digital Treatment Hub and one-on-one fertility coaching delivered by trained clinicians. The kits are marketed to individuals and couples (heterosexual, LGBTQ+, and single parents by choice) seeking an at-home alternative between timed intercourse and clinical IUI.

Is Bea Fertility a public or private company?

Bea Fertility is a private company. It is classified as venture growth investor backed and is currently operating.

When was Bea Fertility founded?

Bea Fertility was founded in 2020. It employs 11 to 50 people.

Where is Bea Fertility based?

Bea Fertility is headquartered in London, United Kingdom, in the Europe region.

How does Bea Fertility make money?

Two revenue lines are on record. Fertility Treatment Kit Sales are the primary driver. The others are fertility Coaching Services.

Who are Bea Fertility's main competitors?

Emerging players on record are Natalist, Modern Fertility and OvuSense. Direct peers are Mosie Baby, PherDal and Frida (Frida Fertility). Broad incumbents are Maven Clinic, Carrot Fertility, Kindbody and Progyny.

Does Bea Fertility have an API?

No public API is recorded for Bea Fertility.

What industry is Bea Fertility in?

Bea Fertility's product category is At-Home Fertility Treatment. Its primary akta.pro industry code is HLALAHAA, Fertility & Reproductive Endocrinology Telehealth (IVF/IUI, infertility evaluation), with a secondary code of HLAFAJAD, Fertility, Reproductive Endocrinology & IVF Centers. Its NAICS code is 621410 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
7PcWhy we invested: Bea FertilityBea Fertility has developed an intracervical insemination applicator that allows individuals to attempt pregnancy at home, significantly reducing costs compared to traditional IVF. The device reportedly achieves a 39.28% pregnancy rate across three treatment cycles, which surpasses the success rate of a first IVF attempt. The fertility market is substantial, representing a $75 billion addressable market in the US, highlighting the demand for affordable reproductive solutions.7Pc7percent VenturesBea Fertility has developed a hormone-free intracervical insemination applicator that aims to provide at-home fertility treatment with pregnancy rates surpassing initial IVF attempts. The device, which utilizes a cervical cap to concentrate sperm near the uterus, has achieved a 39.28% pregnancy rate across three cycles and resulted in at least 29 live births as of June 2024.cosmeticsdesign-europe.com3 trends impacting beauty & personal care innovation in 2024The Future Laboratory's 2024 Innovation Debrief Report identifies three trends: gynaeguity, elastic luxury, and biophilic bonds. It cites Béa Fertility's at-home fertility treatment and LVMH's Olympic sponsorship as examples. The report also notes fragrance brands may host immersive popups.AinAustrian fund Calm/Storm invests in Béa Fertility during €2.9M roundBéa Fertility raised €2.9 million from Octopus Ventures, JamJar, Forward Partners, and Q Ventures, with Austrian fund Calm/Storm participating as an existing investor. The funds will be used to produce at-home fertility treatment kits for Intracervical Insemination, with over 1,000 people already signed up.Tech.euBéa Fertility raises £2.5 million to launch its at-home fertility treatment in the UKBéa Fertility raised £2.5 million to launch its at-home fertility treatment in the UK, offering Intracervical Insemination without hormone injections. The kit costs £700 for a three-month treatment, claimed to be one-twentieth of IVF cost, with 50% efficacy over six cycles. The company is also piloting with the NHS.Business InsiderBéa Fertility wants to provide an at-home alternative to IVF. Check out the 9-slide pitch deck the startup used to secure $3.2 million.Béa Fertility raised $3.2 million from Octopus Ventures to develop an at-home intracervical insemination device. The kit, priced at £350 initially, aims to offer a cheaper alternative to IVF, which costs up to £5,000 per cycle. The startup plans a UK consumer launch and an NHS pilot program.WeglobalstudiosLondon-based healthtech Béa Fertility raises €2.9 million to roll out inclusive at-home fertility treatmentLondon-based healthtech startup Béa Fertility has raised €2.9 million in funding to launch its first at-home fertility treatment in the UK. The investment round was led by Octopus Ventures, with participation from JamJar, Forward Partners, and existing investors Calm/Storm and Q.FinSMEsBéa Fertility Raises $3.2M in FundingBéa Fertility, a London-based fertility tech startup, raised $3.2 million in a funding round to advance clinical-grade at-home fertility care. This funding brings their total to $4.2 million, and the company plans to launch its initial at-home fertility treatment in the UK for early adopters. Additionally, Béa Fertility is initiating a pilot program to trial the use of its treatment kit within the NHS in partnership with South Fulham Primary Care Network.Tech Funding NewsLondon's Béa Fertility nets £2.5M for its revolutionary at-home treatment kits — TFNLondon-based fertility tech startup Béa Fertility has raised £2.5 million in funding led by Octopus Ventures to launch its at-home Intracervical Insemination (ICI) treatment kits. The company is simultaneously initiating a pilot program with the NHS, allowing GPs to refer patients for these inclusive fertility services. This funding supports the commercial rollout of the kits and a large-scale observational study to gather efficacy data on the non-invasive treatment.